

An update and audit of the St. George's Classification Algorithm of Primary Lymphatic Anomalies: A clinical and molecular approach to diagnosis

Kristiana Gordon^{1,2,*}, Ruth Varney^{1,*}, Vaughan Keeley^{2,3}, Katie Riches^{2,3}, Steve Jeffery¹, Malou Van Zanten^{1,2}, Peter Mortimer¹, Pia Ostergaard¹, Sahar Mansour^{1,2,4}

¹Lymphovascular Research Unit, Molecular and Clinical Sciences Research Institute, St. George's, University of London, London SW17 0RE, UK.

²VASCERN PPL European Reference Centre.

³Lymphoedema Clinic, University Hospitals of Derby and Burton, Derby, UK.

⁴SW Thames Regional Genetics Service, St. George's University Hospital NHS Foundation Trust, London, UK.

*Joint first authors.

Corresponding author: Prof Sahar Mansour, smansour@sgul.ac.uk, 020 8725 0569

Contributorship Statement:

KG, VK, KR, PM, and SM were the clinicians involved in seeing and assessing the patients.

RV, MVZ and SM conducted the audit.

PO, PM and SJ revised the manuscript and figures

All authors contributed to the writing of this manuscript.

ABSTRACT

Primary lymphatic anomalies may present in a myriad of ways and are highly heterogenous. Careful consideration of the presentation can lead to an accurate clinical and/or molecular diagnosis which will assist with management. The most common presentation is lymphoedema, swelling resulting from failure of the peripheral lymphatic system. However, there may be internal lymphatic dysfunction e.g. chylous reflux, or lymphatic malformations, including the thorax or abdomen. A number of causal germline or postzygotic gene mutations have been discovered. Some through careful phenotyping and categorisation of the patients based on the St George's classification pathway/algorithm. The St. George's classification algorithm is aimed at providing an accurate diagnosis for patients with lymphoedema based on age of onset, areas affected by swelling, and associated clinical features. This has enabled the identification of new causative genes.

This update brings the classification of primary lymphatic disorders in line with the International Society for the Study of Vascular Anomalies (ISSVA) 2018 classification for Vascular Anomalies. The St George's algorithm considers combined vascular malformations and primary lymphatic anomalies. It divides the types of primary lymphatic anomalies into lymphatic malformations and primary lymphoedema. It further divides the primary lymphoedema into syndromic, generalised lymphatic dysplasia with internal/systemic involvement, congenital onset lymphoedema, and late onset lymphoedema. An audit and update of the algorithm has revealed where new genes have been discovered and that a molecular diagnosis was possible in 26% of all patients overall and 41% of those tested.

Key Words: Primary lymphatic anomaly, primary lymphoedema, generalised lymphatic dysplasia, lymphangiectasia, lymphatic malformations, Hennekam syndrome, Milroy disease, *PIEZO1*, *FAT4*, *EPHB4*, *ADAMTS3*, *FBXL7*, *PIK3CA*, *CELSR1*, vascular anomalies, WILD syndrome, postzygotic mosaicism, vascular disorders, inherited lymphoedema, congenital lymphoedema, lymphoedema praecox, central conducting lymphatic anomaly (CCLA), generalised lymphatic anomaly (GLA).

INTRODUCTION

The lymphatic system is a network of vessels important for whole body fluid homeostasis, lipid absorption, and immune cell trafficking.[1 2] Lymphoedema is caused by lymphatic dysfunction, which leads to a build-up of interstitial fluid within the tissues. This manifests with swelling of the extremities, usually of the legs but may involve other regions or segments of the body such as the upper limbs, face, trunk or genital area. There is an increased risk of infection due to disturbances in immune cell trafficking within the segment of compromised lymph drainage.[3] Lymphatic dysfunction within the thorax and abdomen, here referred to as systemic/internal involvement (but can be referred to as visceral or central involvement), may present with pleural or pericardial effusions or ascites, any of which may be chylous, as well as intestinal or pulmonary lymphangiectasia, protein losing enteropathy or chylous reflux.

The International Society for the Study of Vascular Anomalies (ISSVA) updated their classification for Vascular Anomalies in 2018.[4] The vascular malformations are subgrouped into ‘combined’, which include more than one type of vessel, ‘simple’ (only involving one vessel type), and those ‘associated with other anomalies’.

Lymphoedema due to a presumed genetic developmental fault in the structure or function of lymph conducting pathways is called primary lymphoedema.[5] Some developmental faults can lead to overt structural defects of the lymph conducting pathways and are called lymphatic malformations. Such malformations if interfering with lymph drainage cause lymphoedema (truncal malformations) but some lymphatic malformations remain as isolated anomalies with no connection to main lymph drainage pathways and do not cause lymphoedema (non-truncal malformations).[6] A primary lymphatic anomaly is an umbrella term referring to all lymphatic abnormalities arising from a developmental fault.

For a long time, the diagnosis of primary lymphoedema was based largely on the age of presentation of the swelling, congenital, pubertal and late onset, with limited differentiation between the phenotypes. The discovery of the first causal gene, Vascular Endothelial Growth Factor Receptor 3 for Milroy disease, indicated that a molecular diagnosis was possible.[7] The first St George's classification algorithm of primary lymphoedema and other primary lymphatic disorders was an attempt to guide a clearer categorisation of phenotypes and enable the discovery of further causal genes.[8] Age of onset remained a key criterion, but the sites affected and associated features e.g. dysmorphism, distichiasis (aberrant eyelashes), varicose veins, vascular malformations, and limb overgrowth were also considered, as was internal or systemic involvement e.g. fetal hydrops, intestinal lymphangiectasia, pleural and pericardial effusions, and chylous reflux. A family history of lymphoedema with determination of the mode of inheritance was considered useful.

More rigorous phenotyping facilitated the identification of subgroups of patients with the same broad category of primary lymphatic anomaly. These cohorts were then used for molecular studies to identify more causal genes. Once the genotype was known then crosschecking of the clinical characteristics, natural history and inheritance patterns was

possible and an accurate phenotype defined. Investigations such as lymphoscintigraphy helped to refine the phenotype further and give insight into the mechanisms for the development of the lymphatic disorder. A first update of the classification was published in 2013.[9]

The St. George's classification algorithm is intended to help clinicians categorise their patients and guide testing towards, where possible, a molecular diagnosis. This algorithm is criteria matching i.e. using certain key findings for classification through a multi-step process of history taking, examination findings, mutation testing etc. The next step using the information gathered is to advise on natural history, prognosis and risk (including genetic counselling) and to guide management. While a molecular diagnosis should provide the most specific and accurate diagnosis, it can be seen particularly with the postzygotic mosaic disorders that one genotype can be clinically very heterogenous so there will probably always be a place for good clinical phenotyping supported by investigation to guide management.

Here we present a second update of the St. George's classification algorithm to include newly discovered genes and to bring it in-line with the 2018 ISSVA (International Society for the Study of Vascular Anomalies) classification for Vascular Anomalies.[4]. The results of an audit, the purpose of which was to determine how well the algorithm was performing as a diagnostic aid to classify patients with primary lymphatic anomalies and guide molecular testing are also presented.

METHOD

St. George's classification algorithm of primary lymphatic anomalies

The St. George's classification algorithm was updated (Figure 1) and then applied, retrospectively, to all patients presenting to the national multidisciplinary 'Primary and Paediatric Lymphoedema' Clinic held at St. George's Hospital over a one-year period.

Careful phenotyping was undertaken both on clinical grounds and after selective investigations e.g. lymphoscintigraphy. Where possible and appropriate, targeted genetic testing was performed (this was prior to the introduction of a lymphoedema gene panel in our unit) for some of the genes listed in Table 1.

Table 1. An overview of genetic disorders with primary lymphoedema as a frequent and dominant feature, categorised by inheritance and age of onset. Their position in the classification pathway is indicated by the same colour coding as used in Figure 1. For each disorder, the causal gene, Orphanet and OMIM IDs are given where known.

	Disorder	ORPHANET	OMIM	GENE	
Autosomal dominant	Late onset (>1 year)	Lymphoedema distichiasis syndrome (LDS)	33001	153400	FOXC2
		Late onset 4-limb lymphoedema		613480	GJC2
		Emberger syndrome / Primary lymphoedema with myelodysplasia	3226	614038	GATA2
		Late-onset hereditary lymphoedema			CELSR1
		Meige disease	90186	153200	?
	Congenital (<1 year)	Milroy disease	79452	153100	VEGFR3/FLT4
		Congenital primary lymphoedema of Gordon		615907	VEGFC
		Microcephaly-chorioretinopathy-lymphoedema syndrome	2526	152950	KIF11
		Capillary malformation-arteriovenous malformation (CMAVM)		608354 618196	RASA1 EPHB4
		Autosomal dominant lymphatic-related fetal hydrops (LRFH)		617300	EPHB4
		Hypotrichosis-lymphoedema-telangiectasia-renal defect syndrome (HLTRS)	69735	137940	SOX18
Autosomal recessive	Hypotrichosis-lymphoedema-telangiectasia syndrome (HLTS)	69735	607823	SOX18	
	Hennekam-lymphangiectasia-lymphoedema syndrome Type 1, 2 and 3	2136	235510 616006 618154	CCBE1 FAT4 ADAMTS3	
	Generalised lymphatic dysplasia of Fotiou		616843	PIEZO1	
Mosaicism	PIK3CA-related overgrowth spectrum (PROS)		171834	PIK3CA	
	Mosaic RASopathies			e.g. KRAS/NRAS/HRAS/MAP2K1	

Within the St. George's classification algorithm (Figure 1) there are five main categories of primary lymphatic anomalies. These are presented in the form of colour-coded sections with

the individual subtypes (including genotypes) within the categories. For definitions of some of the terms used see Glossary of Terms (Supplementary Section).

First, the yellow section includes the ‘vascular malformations associated with other anomalies’ and the ‘lymphatic malformations’ (as defined in the introduction).

Secondly, the patient is assessed for syndromes that have lymphoedema as a non-dominant feature (blue section), e.g. the patient is dysmorphic with learning difficulties and possibly has other abnormalities.

Then if not obviously syndromic, and the lymphatic problems are the dominant feature, further assessment and investigations for systemic/internal lymphatic dysfunction or central conducting anomalies (e.g. chylothoraces, chylopericardial effusions, ascites or protein losing enteropathy) are undertaken (pink section). These include a careful medical history asking specifically about prenatal history (e.g. hydrothoraces, fetal hydrops), chronic diarrhoea, abdominal bloating or discomfort with fatty foods, weight loss or faltering growth (in a child), or shortness of breath on exertion. Blood investigations (including serum albumin, immunoglobulins, lymphocyte subsets, faecal levels of calprotectin or alpha-1-antitrysin), echocardiograms and chest radiographs are helpful if central lymphatic dysfunction is suspected.

Where none of the above features are present, then the age of onset is used to determine the grouping; the green section deals with congenital-onset primary lymphoedema (includes syndromes where lymphoedema is the dominant clinical problem, and which is present at birth or develops within the first year of life but is not associated with systemic/internal lymphatic dysfunction). The purple section addresses late-onset primary lymphoedema (i.e. lymphoedema that is the dominant clinical problem, and which develops after the first year of life but is not associated with systemic/internal lymphatic dysfunction). It was decided not to differentiate between pubertal onset (*praecox*) and later onset in life (*tarda*) when it was discovered that one genotype such as *FOXC2* can cause both.

It is important to note that the specific diagnosis may be difficult in a neonate presenting with isolated congenital primary lymphoedema. A baby born with lymphoedema, may later present with developmental delay, systemic involvement, progressive segmental overgrowth or a vascular malformation, which could suggest a diagnosis in one of the other categories. It should also be emphasised that each colour coded section is not exclusive. Some somatic overgrowth anomalies may possess significant internal involvement. Also, lymphoedema distichiasis syndrome is allocated to the purple late onset lymphoedema section because the dominant feature is the late onset lymphoedema not the associated features, which make it a syndrome. Whereas the blue 'syndromic' section refers to conditions with a collection of features where lymphoedema is not the main characteristic. The algorithm is intended to guide a clinical diagnosis and target gene testing.

Genetic methodology

For the purposes of the audit, targeted genetic testing of *FOXC2*, *VEGFR3*, *CCBE1*, *SOX18*, *RASopathy* genes and *PIK3CA* was performed by Sanger sequencing of DNA extracted from lymphocytes or skin fibroblasts in patients in whom a specific genetic diagnosis was suspected. This was before the introduction of a lymphoedema gene panel. Some patients, who were either negative for the targeted genes or did not fit the relevant phenotypes of those genes, were included in WES cohorts after classification, which then led to the identification of new disease genes such as *EPHB4*, *GATA2*, *PIEZO1*, *GJC2* and *FAT4*.

Retrospective audit of the St. George's Clinic for 2016

A 12-month retrospective audit for the year 2016 (1st January 2016 – 31st December 2016) was performed. The aim of the audit was to look at the proportion of patients in each category of the classification algorithm and to look at the success of making a molecular diagnosis through use of the algorithm. The audit criteria required the patients to be seen in our specialist clinic, at any age, with a diagnosis of a primary lymphatic anomaly with data collected from medical records and laboratory results.

RESULTS

Over a 12-month period in 2016, 227 patients were seen (age range 2 weeks to 70 years), 25.6% (n=58/227) of which were new patients. Over one third (38%) of patients seen in the clinic had a family history of primary lymphoedema.

Few patients had received genetic testing prior to referral to the clinic. Targeted genetic testing was completed in 63% (n=143) of the patients seen. At that time, a lymphoedema gene panel was not available, Patients were only tested if the clinician felt there was a reasonable chance of finding a molecular cause – i.e. testing was targeted.

Of those tested, the underlying genetic cause was identified in 41% (n=59/143). Overall, a molecular diagnosis was made in 26% (59/227) of all the patients seen in 2016.

1. Vascular malformations with associated anomalies and lymphatic malformations (yellow)

This group presents with malformations in the structure and organisation of blood and lymphatic vessels with a patchy, segmental distribution. Lymphoedema may develop in combination with vascular malformations and segmental overgrowth (or occasionally, undergrowth) of tissues within the swollen limb e.g. muscle, skeletal or adipose tissues (Figure 2A). The combination of lymphatic and vascular malformations in this group reflects the mutual embryological origins of the two vascular systems.

These conditions are usually due to postzygotic mutations e.g. PROS (*PIK3CA*-Related Overgrowth Spectrum). Exceptions to this are capillary malformation-arteriovenous malformation (MIM 608354) such as Parkes-Weber syndrome, which may be caused by heterozygous, germline mutations in *RASA1*. [10]

Of the 227 patients seen in 2016, 17% (n=39) had lymphoedema associated with vascular malformations and/or segmental over- (or under-) growth (Figure 2, pie chart) in comparison with 15% in 2010. [8] It has been shown that postzygotic, gain of function mutations in *PIK3CA* may be responsible for many of the mosaic segmental overgrowth spectrum disorders. [11] Postzygotic mutations are rarely identified in blood samples and therefore require a skin biopsy of the affected region. In the 2016 cohort, only 10 patients (26%) provided skin biopsies for genetic analysis, producing just one molecular diagnosis. More research in this field is required to identify the genetic basis for some of the conditions in this category. However, since the last revision, we have gained a much better understanding of

the classification of some of these postzygotic mosaic conditions, therefore a brief review of the latest developments in this area is given in the Supplementary Section.

2. Syndromic lymphoedema (blue)

Syndromes associated with primary lymphatic anomalies are listed in Table 2 and include chromosomal abnormalities, single gene disorders and imprinting disorders. Patients attending the clinic with syndromic primary lymphoedema made up 13% (n=29) (Figure 2, pie chart), similar to the 15% reported by Connell *et al.*[8] Nearly three-quarters (72%, n=21) of this cohort had a molecular or chromosomal diagnosis. The most frequently seen syndromes were Noonan syndrome (n=8) (Figure 2B); Turner syndrome (n=4) and Phelan McDermid syndrome (n=3).

Table 2. An overview of ‘Known Syndromes’ with primary lymphoedema as a non-dominant association as referred to in the St. George’s classification algorithm (Figure 1, blue section). The syndromes are categorised by mode of inheritance. The causal genes or structural variants and OMIM number are indicated where known.

Syndromes caused by chromosomal abnormality		OMIM	Chromosome
Phelan McDermid syndrome		606232	22q terminal deletion or ring chromosome 22
Prader Willi syndrome		176270	15q11 microdeletion or maternal UPD 15
Thrombocytopenia with absent radius		274000	1q21.1 microdeletion and <i>RBM8A</i>
Turner syndrome			45,X0
Velocardiofacial syndrome		192430	22q11 microdeletion
Syndromes caused by single gene fault		OMIM	Gene(s)
Autosomal dominant	Noonan/Cardiofaciocutaneous syndrome	163950	<i>PTPN11, RIT1, RAF1, SOS1, KRAS, BRAF, MAP2K1, MAP2K2</i> plus others
	CHARGE syndrome	214800	<i>CDH7</i>
	Microcephaly-chorioretinopathy-lymphoedema-intellectual disability (MCLID)	152950	<i>KIF11</i>
	Oculo-dento-digital syndrome	164200	<i>GJA1</i>
	Hypotrichosis-lymphoedema-telangiectasia-renal-defect syndrome	137940	<i>SOX18</i>
	Ruvalcaba syndrome	180870	<i>PTEN</i>
	Costello syndrome	218040	<i>HRAS</i>
	Sotos syndrome	117550	<i>NSD1</i>
	Tuberous sclerosis	191100	<i>TSC1, TSC2</i>
Autosomal recessive	Carbohydrate deficient glycoprotein types 1a, 1b, and 1h	212065, 602579, 608104	<i>PMM2, PM1, ALG8</i>
	Choanal atresia-lymphoedema	613611	<i>PTPN14</i>
	Cholestasis-lymphoedema syndrome (Aagenaes syndrome)	214900	
	Hennekam-lymphangiectasia-lymphoedema syndrome Type 1, 2 and 3	235510, 616006	<i>CCBE1, FAT4, ADAMTS3</i>
	Hypotrichosis-lymphoedema-telangiectasia syndrome	607823	<i>SOX18</i>
X-linked	Ectodermal dysplasia, anhidrotic, immunodeficiency, osteopetrosis and lymphoedema (OL-EDA-ID syndrome)	300301	<i>IKBKG (NEMO)</i>
	Fabry disease	301500	<i>GLA</i>
Somatic	CLOVES syndrome Macrocephaly-capillary-malformation (MCAP)	602501	<i>PIK3CA</i>
Syndromes with no known cause		OMIM	
Irons-Bianchi syndrome		601927	
Mucke syndrome		247440	
Progressive encephalopathy, hysarrhythmia, optic atrophy (PEHO)		260565	
Yellow nail syndrome		153300	

3. Lymphoedema with pre- or postnatal systemic involvement (pink)

In some conditions, lymphoedema may be associated with internal (systemic or visceral)

disturbances of the lymphatic system within thorax or abdomen e.g. fetal hydrops, intestinal

lymphangiectasia (presenting as protein-losing enteropathy), pulmonary lymphangiectasia, or with pericardial and/or pleural effusions (often chylous), or chylous reflux (often into the genitalia). Broadly, there are two types of lymphoedema with systemic involvement: (A) ‘widespread’ swelling affecting all segments of the body (Figure 2C), such as that seen in generalised lymphatic dysplasia (GLD). Due to faulty development, the structural or functional abnormality of the lymphatic system is affecting the whole body. One type is Hennekam-lymphangiectasia-lymphoedema syndrome[12]. (B) ‘patchy’ areas of swelling e.g. left arm and right leg, which have been named ‘multisegmental lymphatic dysplasia’ (MLD) (Figure 1).

Prenatally, these conditions may present with pleural effusions (hydrothoraces), or as non-immune fetal hydrops (the accumulation of fluid in at least two compartments of a fetus such as the abdominal cavity, pleura, or subcutaneous oedema). 15% of non-immune cases of hydrops are the result of lymphatic disorders, and approximately 20% are idiopathic, some of which may be due to, as yet, unidentified lymphatic abnormalities.[13]

In our audit, this cohort accounted for 12% (n=27) of patients (Figure 2, pie chart), slightly higher than the 8% reported in 2010.[8] Molecular testing was carried out in 17 patients. Nine of those tested had generalised lymphatic dysplasia (GLD), and pathogenic variants were identified in seven (78%). Five had biallelic variants in the *PIEZO1* gene and one each with biallelic variants in *FAT4* and *SOX18*. Interestingly, two of the families described by Connell and colleagues in 2010, cases 3 and 4, have subsequently been found to be caused by biallelic variants in the *PIEZO1* gene.[8 14]

None of the eight patients, who presented with ‘patchy’ distribution of lymphoedema (MLD), had an identifiable molecular diagnosis. It is suspected that these patients could have a postzygotic mosaic mutation or WILD syndrome.[15]

Since the last revision of the St. George's classification algorithm was published,[9] five new causal genes associated with GLD and/or non-immune fetal hydrops have been identified: *ADAMTS3*,[16] *EPHB4*,[17] *FAT4*,[18] *FBXL7*,[19] and *PIEZO1*[14 20] and are reviewed in the Supplementary Section.

4. Congenital onset lymphoedema (green)

In this category, congenital onset is defined as lymphoedema that is present at birth or develops within the first year of life. Bilateral lower limb swelling is the most frequent presentation (Figure 2D), but the swelling may be unilateral and/or involve the arms, genitalia and/or face, depending on the underlying cause. There are a number of different genetic disorders presenting with congenital lymphoedema (Table 1). Milroy disease (ORPHA79452; MIM 153100) is the commonest form, occurring as a result of pathogenic variants in *FLT4/VEGFR3*. [21 22] The mutation may occur *de novo*, so a family history is not essential for this diagnosis. The lymphoedema is always confined to the lower limbs but may be unilateral, and may (rarely) involve the genitalia. Approximately 10% of mutation carriers do not have lymphoedema. Fetuses with Milroy disease may present antenatally with pedal oedema in the third trimester, but also, in a few cases, with bilateral hydrothoraces, which resolve before birth.

Pathogenic variants in *VEGFC*, the ligand for *VEGFR3*, have also been identified in association with congenital primary lymphoedema of Gordon (MIM 615907), also affecting the lower limbs.[23-26]

The congenital category represents 21% (n=47) of the patients seen in 2016 (Figure 2, pie chart) compared to 24% in 2010.[8] A pathogenic variant was identified in 19 of the 47 (40%) patients genetically tested in this category. The majority (n=18) had pathogenic variants identified in *FLT4/VEGFR3* and, in one patient, a pathogenic variant in the *GJC2*

gene. A *GJC2* mutation in a patient presenting with lymphoedema at birth is unusual but shows the variability of the phenotype.

Many of the conditions listed under the other categories in the classification algorithm may initially present with congenital lymphoedema but systemic involvement, progressive overgrowth or vascular malformation may present later and are so reclassified. Likewise, some syndromic forms may present with congenital lymphoedema before any other manifestations, making diagnosis difficult at times. Thus, the diagnosis of ‘isolated’ congenital primary lymphoedema may be difficult in a neonate presenting with pedal oedema. Therefore, a molecular diagnosis in the neonatal period is clinically very useful in the management of these patients.

5. Late onset lymphoedema (purple)

‘Late onset’ lymphoedema is defined as presenting after the first year of life. Swelling can range from being unilateral, bilateral or can involve all 4 limbs and can present from early childhood up to adulthood (Figures 1 and 2E). Some may present with unilateral swelling, but the contralateral limb may become involved later or show abnormalities on lymphoscintigram even when clinically uninvolved. The phenotypes also range from mild to severe. There are currently five genes known to be associated with late onset lymphoedema: *FOXC2* (Figure 2F),[27] *GJC2*,[28 29] *GATA2* (Figure 2G),[30] *HGF*,[31] and *CELSRI*[32] (Table 1). For many patients the molecular cause remains elusive, particularly in those patients with Meige disease and late onset (usually pubertal) unilateral lower limb lymphoedema.

Late onset primary lymphoedema accounted for 37% (n=85) in 2016 (Figure 2, pie chart) comparable to the 36% reported in 2010.[8] This category has a low number of molecular diagnoses (n=12; 14%) as there are currently no causative genes for Meige disease, which made up 36% (n=31) of patients in this category.

DISCUSSION

This review presents an updated St. George's classification algorithm of primary lymphatic anomalies and brings it in-line with the ISSVA classification for Vascular Anomalies. It cites eight new causative genes since the last publication and highlights the areas where the genetic basis is still not known. This rapidly evolving field demonstrates that primary lymphoedema and vascular malformations are highly heterogenous.

The audit reports an overall successful molecular diagnosis in 26% of patients seen in the clinic, but 41% of those patients selected for molecular testing. This is a considerable improvement on the rate of a molecular diagnosis since the algorithm was first published in 2010. Only two causal genes were known at that time. We can conclude from the audit that the algorithm works well in targeting mutation testing. Furthermore, use of the algorithm has led to the discovery of a number of causal genes. While it could be argued that the introduction of the lymphoedema gene panel obviates any need for targeted gene tests, we believe that matching a phenotype to a likely gene reduces wasteful testing and helps enormously in the interpretation of variants of unknown significance, which are becoming an increasing problem in the era of next generation sequencing.

Although providing a molecular diagnosis in one quarter of all the patients with primary lymphoedema represents a considerable improvement from when the algorithm was last reviewed, the molecular diagnosis is still not identified in the majority of patients seen in the St. George's clinic. In the diagnostic setting, the introduction of next generation sequencing with a targeted (virtual) 'lymphoedema gene panel' may improve the diagnostic rate and broaden the phenotypic spectrum of many of the known genetic disorders. Understanding of the natural history of the disorder will enable appropriate surveillance of e.g. leukaemia in Emberger syndrome (*GATA2*), and allow investigations for known associated problems, e.g. congenital heart disease in patients with lymphoedema distichiasis syndrome (*FOXC2*).

Prenatal diagnosis for the more serious conditions also becomes possible. Knowledge of causal genes, and mechanisms of pathophysiology, provide an opportunity for new, improved treatments (personalised medicine) (e.g. mTOR inhibitors for progressive overgrowth disorders).

In conclusion, the St. George's classification algorithm for primary lymphatic anomalies has been further refined. With this review we have provided insight into the most recently discovered genotypes and how this algorithm can be used in the clinic to guide management of primary lymphoedema patients.

ACKNOWLEDGEMENTS

We extend our thanks to the patients and their families who have participated in our work. Five of the authors of this publication are members of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN) - Project ID: 769036. We would also like to thank the other members of the Primary and Paediatric Lymphoedema Working Group (PPL-WG) of the VASCERN consortium for their interest in our work and invaluable discussions.

COMPETING INTEREST

All authors declare no conflict of interest.

FUNDING

We would like to extend our thanks to the British Heart Foundation for funding our work.

WEB RESOURCES

OMIM, <http://www.omim.org/>.

Orphanet, <https://www.orpha.net>

ISSVA, <http://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf>

REFERENCES

1. Mortimer PS and Rockson SG. New developments in clinical aspects of lymphatic disease. *Journal of Clinical Investigation*. 2014;124:915-921.
2. Aspelund A, Robciuc MR, Karaman S, Makinen T and Alitalo K. Lymphatic System in Cardiovascular Medicine. *Circ Res*. 2016;118:515-30.
3. Moffatt CJ, Franks PJ, Doherty DC, Williams AF, Badger C, Jeffs E, Bosanquet N and Mortimer PS. Lymphoedema: an underestimated health problem. *Qjm-an International Journal of Medicine*. 2003;96:731-738.
4. ISSVA. Classification of Vascular Anomalies ©2018 International Society for the Study of Vascular Anomalies. 2018.
5. Browse NL and Stewart G. Lymphoedema: pathophysiology and classification. *J Cardiovasc Surg (Torino)*. 1985;26:91-106.
6. Lee BB, Andrade M, Antignani PL, Boccardo F, Bunke N, Campisi C, Damstra R, Flour M, Forner-Cordero I, Gloviczki P, Laredo J, Partsch H, Piller N, Michelini S, Mortimer P, Rabe E, Rockson S, Scuderi A, Szolnoky G and Villavicencio JL. Diagnosis and treatment of primary lymphedema. Consensus document of the International Union of Phlebology (IUP)-2013. *Int Angiol*. 2013;32:541-74.
7. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K and Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. *Nature Genetics*. 2000;25:153-159.
8. Connell F, Brice G, Jeffery S, Keeley V, Mortimer P and Mansour S. A new classification system for primary lymphatic dysplasias based on phenotype. *Clinical Genetics*. 2010;77:438-452.

9. Connell FC, Gordon K, Brice G, Keeley V, Jeffery S, Mortimer PS, Mansour S and Ostergaard P. The classification and diagnostic algorithm for primary lymphatic dysplasia: an update from 2010 to include molecular findings. *Clinical Genetics*. 2013;84:303-314.
10. Revencu N, Boon LM, Mulliken JB, Enjolras O, Cordisco MR, Burrows PE, Clapuyt P, Hammer F, Dubois J, Baselga E, Brancati F, Carder R, Quintal JM, Dallapiccola B, Fischer G, Frieden IJ, Garzon M, Harper J, Johnson-Patel J, Labreze C, Martorell L, Paltiel HJ, Pohl A, Prendiville J, Quere I, Siegel DH, Valente EM, Van Hagen A, Van Hest L, Vaux KK, Vicente A, Weibel L, Chitayat D and Vikkula M. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. *Hum Mutat*. 2008;29:959-65.
11. Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W and Biesecker LG. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. *Am J Med Genet A*. 2015;167A:287-95.
12. Hennekam RCM, Geerdink RA, Hamel BCJ, Hennekam FAM, Kraus P, Rammeloo JA and Tillemans AAW. Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental-retardation. *American Journal of Medical Genetics*. 1989;34:593-600.
13. Bellini C, Donarini G, Paladini D, Calevo MG, Bellini T, Ramenghi LA and Hennekam RC. Etiology of non-immune hydrops fetalis: An update. *Am J Med Genet A*. 2015;167A:1082-8.
14. Fotiou E, Martin-Almedina S, Simpson MA, Lin S, Gordon K, Brice G, Atton G, Jeffery I, Rees DC, Mignot C, Vogt J, Homfray T, Snyder MP, Rockson SG, Jeffery S, Mortimer PS, Mansour S and Ostergaard P. Novel mutations in PIEZO1 cause an autosomal

recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. *Nature Communications*. 2015;6:8085.

15. Kreuter A, Hochdorfer B, Brockmeyer NH, Altmeyer P, Pfister H, Wieland U and Competence Network HA. A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia - WILD syndrome. *Archives of Dermatology*. 2008;144:366-372.

16. Brouillard P, Dupont L, Helaers R, Coulie R, Tiller GE, Peeden J, Colige A and Vikkula M. Loss of ADAMTS3 activity causes Hennekam lymphangiectasia-lymphedema syndrome 3. *Hum Mol Genet*. 2017;26:4095-4104.

17. Martin-Almedina S, Martinez-Corral I, Holdhus R, Vicente A, Fotiou E, Lin S, Petersen K, Simpson MA, Hoischen A, Gilissen C, Jeffery H, Atton G, Karapouliou C, Brice G, Gordon K, Wiseman JW, Wedin M, Rockson SG, Jeffery S, Mortimer PS, Snyder MP, Berland S, Mansour S, Makinen T and Ostergaard P. EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis. *Journal of Clinical Investigation*. 2016;126:3080-3088.

18. Alders M, Al-Gazali L, Cordeiro I, Dallapiccola B, Garavelli L, Tuysuz B, Salehi F, Haagmans MA, Mook OR, Majoie CB, Mannens MM and Hennekam RC. Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome. *Human Genetics*. 2014;133:1161-1167.

19. Boone PM, Paterson S, Mohajeri K, Zhu W, Genetti CA, Tai DJC, Nori N, Agrawal PB, Bacino CA, Bi W, Talkowski ME, Hogan BM and Rodan LH. Biallelic mutation of FBXL7 suggests a novel form of Hennekam syndrome. *Am J Med Genet A*. 2020;182:189-194.

20. Lukacs V, Mathur J, Mao R, Bayrak-Toydemir P, Procter M, Cahalan SM, Kim HJ, Bandell M, Longo N, Day RW, Stevenson DA, Patapoutian A and Krock BL. Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia. *Nat Commun.* 2015;6:8329.
21. Brice G, Child AH, Evans A, Bell R, Mansour S, Burnand K, Sarfarazi M, Jeffery S and Mortimer P. Milroy disease and the VEGFR-3 mutation phenotype. *Journal of Medical Genetics.* 2005;42:98-102.
22. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K and Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. *American Journal of Human Genetics.* 2000;67:295-301.
23. Gordon K, Schulte D, Brice G, Simpson MA, Roukens MG, van Impel A, Connell F, Kalidas K, Jeffery S, Mortimer PS, Mansour S, Schulte-Merker S and Ostergaard P. Mutation in Vascular Endothelial Growth Factor-C, a Ligand for Vascular Endothelial Growth Factor Receptor-3, Is Associated With Autosomal Dominant Milroy-Like Primary Lymphedema. *Circulation Research.* 2013;112:956-U235.
24. Balboa-Beltran E, Fernández-Seara MJ, Pérez-Muñuzuri A, Lago R, García-Magán C, Couce ML, Sobrino B, Amigo J, Carracedo A and Barros F. A novel stop mutation in the vascular endothelial growth factor-C gene (VEGFC) results in Milroy-like disease. *J Med Genet.* 2014;51:475-8.
25. Fastre E, Lanteigne LE, Helaers R, Giacalone G, Revencu N, Dionyssiou D, Demiri E, Brouillard P and Vikkula M. Splice-site mutations in VEGFC cause loss of function and Nonne-Milroy-like primary lymphedema. *Clin Genet.* 2018;94:179-181.
26. Nadarajah N, Schulte D, McConnell V, Martin-Almedina S, Karapouliou C, Mortimer PS, Jeffery S, Schulte-Merker S, Gordon K, Mansour S and Ostergaard P. A Novel Splice-

Site Mutation in VEGFC Is Associated with Congenital Primary Lymphoedema of Gordon.

Int J Mol Sci. 2018;19:E2259.

27. Fang JM, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH and Glover TW. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. *American Journal of Human Genetics.* 2000;67:1382-1388.

28. Ferrell RE, Baty CJ, Kimak MA, Karlsson JM, Lawrence EC, Franke-Snyder M, Meriney SD, Feingold E and Finegold DN. GJC2 Missense Mutations Cause Human Lymphedema. *American Journal of Human Genetics.* 2010;86:943-948.

29. Ostergaard P, Simpson MA, Brice G, Mansour S, Connell FC, Onoufriadis A, Child AH, Hwang J, Kalidas K, Mortimer PS, Trembath R and Jeffery S. Rapid identification of mutations in GJC2 in primary lymphoedema using whole exome sequencing combined with linkage analysis with delineation of the phenotype. *Journal of Medical Genetics.* 2011;48:251-255.

30. Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Woollard WJ, Dafou D, Kilo T, Smithson S, Lunt P, Murday VA, Hodgson S, Keenan R, Pilz DT, Martinez-Corral I, Makinen T, Mortimer PS, Jeffery S, Trembath RC and Mansour S. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). *Nature Genetics.* 2011;43:929-931.

31. Finegold DN, Schacht V, Kimak MA, Lawrence EC, Foeldi E, Karlsson JM, Baty CJ and Ferrell RE. HGF and MET mutations in primary and secondary lymphedema. *Lymphat Res Biol.* 2008;6:65-8.

32. Gonzalez-Garay ML, Aldrich MB, Rasmussen JC, Guilliod R, Lapinski PE, King PD and Sevvick-Muraca EM. A novel mutation in CELSR1 is associated with hereditary lymphedema *Vasc Cell*; 2016;8:1.
33. Connell FC, Ostergaard P, Carver C, Brice G, Williams N, Mansour S, Mortimer PS, Jeffery S and Lymphoedema C. Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas. *Human Genetics*. 2009;124:625-631.

FIGURES

Figure 1. St. George's classification algorithm for primary lymphatic anomalies. The five main groupings (colour coded) with their various clinical sub-types of disease. Primary lymphoedema is the major clinical feature in the green, pink and purple sections. Text in red indicates the suggested genetic test and/or differential diagnosis for the subgroup, however, the indicated genes do not explain the cause of disease in all patients in each grouping. For example, only 70% of Milroy disease patients are explained by mutations in *FLT4/VEGFR3*. [33] FH, family history; +ve, positive; -ve, negative. (Image shared by St George's Lymphovascular Research Group under the CC BY-SA 4.0 International license on Wikimedia Commons).

Figure 2. A graphic representation of the 227 audited patients seen in clinic in 2016 and their distribution across the five categories from Figure 1 (pie chart). (A-G) Images show features of each category. (A) Patients with postzygotic mutations often present with asymmetrical swelling and segmental overgrowth as this patient, who is mosaic for a mutation in *KRAS*. (B) Webbed neck swelling in Noonan Syndrome. (C) In rare cases, swellings can be widespread affecting all segments of the body such as in this child with a *CCBE1* mutation. (D) In milder forms, often just the dorsum of the foot is affected as in this baby with a *VEGFR3* mutation. (E, F) Lower limb swelling and distichiasis (arrowheads in F) in a patient with a *FOXC2* mutation. (G) Lymphoedema is a major cause of skin disease and affected patients suffer from severe and recurrent episodes of cutaneous infection, especially HPV-associated warts as seen in patients with *GATA2* mutations. GLD, generalised lymphatic dysplasia.

Figure 1




Figure 2



Supplementary Section

RECENTLY DESCRIBED NEW GENETIC ENTITIES

EPHB4 – Autosomal dominant lymphatic-related hydrops fetalis (MIM: 617300)

Heterozygous *EPHB4* mutations were identified following WES in two families, who had a significant family history of antenatal, non-immune fetal hydrops and atrial septal defects consistent with autosomal dominant inheritance.[1] This phenotype is characterised by fetal hydrops or antenatal pleural effusions (or postnatal chylothoraces), which vary in severity and, in several cases, have led to fetal demise. The hydrops may resolve in the neonatal period, but patients may develop peripheral oedema later in life (Supplemental Figure 1A), which mainly affects the legs. A high incidence of early onset and severe varicose veins was observed (Supplemental Figure 1B).

Recently, a pathogenic heterozygous variant in *EPHB4* was identified in a 4-generation family with a central conducting lymphatic anomaly.[2] This family also had a child presenting with fetal hydrops, and probably represents a variation of the same condition. Venous insufficiency was also very prevalent in this family.

Interestingly, pathogenic *EPHB4* variants have also been identified in families and singletons with vein of Galen aneurysmal malformations [3 4] and capillary malformation-arteriovenous malformation [5 6], the latter showing phenotypic overlap with hereditary haemorrhagic telangiectasia.

PIEZO1 - Generalized lymphatic dysplasia of Fotiou (MIM:616843)

PIEZO1-associated hereditary lymphoedema is an autosomal recessive generalized lymphatic dysplasia, often presenting prenatally as fetal hydrops.[7 8] Biallelic loss-of-function mutations in the *PIEZO1* gene cause a variable phenotype. The oedema can be severe, in

some cases leading to perinatal death. However, it may resolve in infancy and may re-present as peripheral lymphoedema during childhood. The swelling frequently involves the lower limbs, genitalia and face (Supplemental Figure 1C, D). There is often swelling of the upper limbs, but this is not as marked (Supplemental Figure 1E). There may be chylothoraces, pericardial effusions and, rarely, intestinal lymphangiectasia.

Heterozygous gain-of-function mutations in *PIEZO1* cause autosomal dominant dehydrated hereditary stomatocytosis (MIM: 194380), a relatively mild anaemia, which may also present with perinatal oedema/fetal hydrops (not due to anaemia).[9 10]

ADAMTS3 - Hennekam lymphangiectasia-lymphoedema syndrome 3 (MIM:618154)

ADAMTS3, together with *CCBE1*, is essential for the proteolytic activation of pro-VEGFC, the ligand for VEGFR3.[11-13] One family, including two affected children, presenting with a severe generalised lymphatic dysplasia (Hennekam lymphangiectasia-lymphoedema syndrome type 3) has been published.[14] The features include: antenatal polyhydramnios, hydroceles, congenital lymphoedema of the lower limbs and genitalia, intestinal lymphangiectasia with a protein losing enteropathy, and distinctive facial features probably secondary to facial oedema. Whole exome sequencing (WES) in the family identified compound heterozygous variants in *ADAMTS3*. Functional analysis of the variants (c.503T>C and c.872T>C) confirmed them to be highly damaging.

FAT4 - Hennekam lymphangiectasia-lymphoedema syndrome 2 (MIM: 616006)

Alders and colleagues described biallelic mutations in *FAT4* in nine patients from five families, who all presented with lymphoedema of the extremities, presenting at birth or in childhood.[15] Seven of the nine had intestinal lymphangiectasia with or without other systemic involvement. Mutations in *FAT4* have previously been found to cause van Maldergem syndrome 2 (MIM: 615546).[16 17] Many features of the two allelic conditions

overlap; including facial dysmorphism (hypertelorism, epicanthus and a flat nasal bridge), impaired cognition, small ears with thick helices and irregular dentition. In addition, van Maldergem syndrome is associated with neonatal hypotonia and feeding problems, hearing loss, tracheal anomalies, and osteopenia[18] and lymphoedema has been reported in one patient (Supplemental Figure 1F).[19]

FBXL7 biallelic mutations associated with Hennekam syndrome

A recent publication describes a homozygous single-exon deletion affecting *FBXL7* in a patient presenting with Hennekam syndrome. Previous studies in *Drosophila* had indicated that *Fbxl7* interacts with *Fat*, of which human *FAT4* is an ortholog. The patient presented shortly after birth with facial and scrotal oedema, which resolved. However, at 3 months of age, he developed persistent bilateral lower limb oedema. Clinically, he had intestinal lymphangiectasia, although this was not confirmed by endoscopic examination. Dysmorphic facies and camptodactyly, in keeping with those seen in Hennekam lymphangiectasia-lymphoedema type 2 (*FAT4*-associated), are described but photographs of the patient are not included.[20]

Mutations in any of the genes in the “Lymphoedema with Systemic Involvement” (pink) category may initially present with congenital lymphoedema, as many of the ‘systemic’ symptoms may not be present at birth but develop later in childhood. Therefore, this group of genes/conditions (*ADAMTS3*, *CCBE1*, *EPHB4*, *FAT4*, *PIEZO1* and *SOX18*) should be considered in any infant presenting with congenital lymphoedema, particularly if the swelling is not confined to the lower limbs, and if the genital region is swollen at birth (Figure 1). This category should be considered in any patient presenting prenatally with fetal hydrops.

CELSR1 associated with hereditary late onset primary lymphoedema

Three recent publications present the identification of truncating variants of *CELSR1* in families with an autosomal dominant, non-syndromic lymphoedema of the lower limbs presenting in childhood and predominantly affecting females.[21-23] Imaging showed extensive dermal backflow with tortuous lymphatic vessels.[22] *CELSR1* is an atypical cadherin involved in planar cell polarity. Previous work had demonstrated a critical role of this gene in intraluminal valve formation in murine lymphatic vessels.[24]

PIK3CA Related Overgrowth Spectrum (PROS)

The PIK3CA-Related Overgrowth Spectrum (PROS) includes a range of mosaic conditions caused by postzygotic, gain-of-function mutations in *PIK3CA*. [25] The phenotypic spectrum of PROS includes disorders which have overlapping clinical features: Fibroadipose hyperplasia[26]; isolated lymphatic malformation;[27] CLOVES (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal)[28] and megalencephaly-capillary malformations (MCAP) and Klippel-Trenaunay syndrome.[25 29] Lymphatic manifestations may, or may not, be present.

The PROS spectrum is characterised by asymmetrical and disproportionate congenital (or early childhood) onset of segmental overgrowth, which may be progressive. Additional features include epidermal naevi, vascular malformations, macrodactyly and macrocephaly. The severity of PROS varies; the overgrowth can be mild with very little progression (e.g. macrodactyly of one digit) or it can be extreme (affecting a range of tissues including adipose, muscular and skeletal) (Supplemental Figure 1G).[26]

Pharmacologic therapy with mTOR inhibitors for patients with progressive overgrowth has been introduced, with variable success in halting the progressive overgrowth.[30-32] Since PROS was originally described, Klippel-Trenaunay syndrome (KTS) has been included

within the spectrum, as *PIK3CA* mutations have been identified in some patients with KTS.[33] However, Proteus syndrome, another mosaic phenotype, remains separate due to the presence of a cerebriform connective tissue naevi (usually on the plantar surface) and distinct causal postzygotic, gain-of-function mutations in the *AKT1* gene.

Mosaic RASopathies

Recent publications describe patients with postzygotic mosaic mutations in the RASopathy genes resulting in high-flow arteriovenous malformations and low-flow vascular malformations with a somatic mosaic distribution.[30] One of these patients (Case 15), was seen in our clinic with congenital, unilateral lymphoedema of the left lower limb (Figure 2C). He required epiphyseal fusion to prevent increasing limb length discrepancy due to segmental overgrowth of the left leg. There was an extensive vascular malformation of the left leg and venous duplex confirmed venous incompetence. Lymphoscintigraphy also confirmed lymph drainage abnormalities. His presentation was consistent with a diagnosis of Klippel-Trenaunay syndrome. A postzygotic mutation, resulting in somatic mosaicism, was identified in the *KRAS* gene with a variant allele frequency (VAF) of only 2% identified in DNA extracted from a skin biopsy from the affected leg. This *KRAS* variant, c.35G>A;p.(Gly12Asp) has previously only been seen in association with cancer but never seen as a germline mutation in Noonan syndrome or Cardiofaciocutaneous syndrome.[34]

We have seen one further patient with an extensive vascular malformation of his right lower limb associated with lymphoedema. A pathogenic *MAP2K1* variant, c.360G>T;p.(Glu120Asp), was identified with a variant allele frequency (VAF) of 49% in DNA extracted from skin fibroblasts in the affected leg. This variant was not seen in the DNA extracted from blood lymphocytes.

Interestingly, different germline mutations in the same genes cause Noonan syndrome and Cardiofaciocutaneous syndrome, both of which are also known to be complicated by lymphatic abnormalities.[35] Therefore, a mosaic RASopathy should be suspected in any patient with segmental overgrowth, vascular malformations with or without lymphoedema, in whom no mutation in *PIK3CA* has been identified.

Supplementary Figure 1: Clinical photos of patients with mutations in some of the new causal genes.

(A-B) Mutations in *EPHB4* cause autosomal dominant lymphatic-related fetal hydrops. In adults it can lead to mild facial oedema (A) and extensive varicose veins (arrow) (B). (C-E) Mutations in *PIEZO1* cause a type of generalised lymphatic dysplasia. Patients can present with facial oedema (C) and four limb lymphoedema (D, E). (F) Typical facies of van Maldergem syndrome caused by mutations in *FAT4*. (G) PROS-overgrowth of left leg with vascular malformation caused by a postzygotic mutation in *PIK3CA*.



GLOSSARY OF TERMS

In order to maximise the utility of the St. George's classification algorithm, it is helpful to define some of the terms used:

Lymphoedema: swelling of an extremity due to lymphatic dysfunction (i.e. not oedema from, for example, heart failure or an allergic reaction). Involvement of one or more extremities is peripheral lymphoedema.

Primary lymphoedema: Lymphoedema due to a developmental fault in the structure or function of the lymph conducting pathways and presumed to be genetic in origin. Thus, it is not **secondary** to an identified cause (e.g. cancer or infection).

Lymphatic malformation: These are overt structural defects of the lymph conducting pathways, which may include **truncal malformations** (if interfering with lymph drainage and cause lymphoedema) or **non-truncal malformations**, (isolated anomalies with no connection to main lymph drainage pathways and do not cause lymphoedema).

Generalised Lymphatic Dysplasia (dys = bad; plasis = formation) is used to describe the abnormal growth/development of the lymphatic system and is a structural or functional abnormality.

Systemic involvement or internal/visceral lymphatic dysfunction: Abnormal lymphatic function causing internal swelling e.g. chylothoraces, chylopericardium, chylous ascites, intestinal or pulmonary lymphangiectasia or non-immune fetal hydrops.

Central conducting lymphatic anomalies (CCLA) is a term that is used to describe dysfunction or obstruction of the lymph conducting channels within the thorax or abdomen as seen on imaging such as contrast-enhanced MR Lymphangiography.[36] This may present as chylothoraces, chylopericardium, ascites and chylous reflux with leaking of lymphatic fluid,

often into the genital area. Causes of CCLA include Noonan syndrome (under ‘Syndromic lymphoedema’ [blue section]),[37] *EPHB4*-associated disorders[2] (under ‘Generalised lymphoedema with systemic involvement’ [pink section]). It is therefore a highly heterogenous, descriptive term rather than a specific entity.

Generalised lymphatic anomaly (GLA) is a term that is easily confused with generalised lymphatic dysplasia (see description above). However, generalised lymphatic anomaly (GLA), also called lymphangiomas, is a rare condition involving the abnormal overgrowth of lymphatic vessels (small and large cystic lymphangiomas) in the lungs, pleura, bones and soft tissue. GLAs may be congenital or acquired. The lymphangiomas may initially be proliferative, but then stabilise over time. In others, they may follow a progressive course and result in life-threatening complications, pain and functional disability. We have included [Gorham-Stout disease \(GSD\)](#) in this category, a condition involving abnormal growth of lymphatic vessels that affects bone.[38] The bony destruction (osteolysis) is progressive in GSD, hence the name “vanishing bone disease”, whereas bony lytic lesions in GLA are less aggressive. Causal mutations have not yet been discovered for GLA or GSD, but therapeutic trials of sirolimus have been successful in some patients.[39]

References for Supplementary Section

1. Martin-Almedina S, Martinez-Corral I, Holdhus R, Vicente A, Fotiou E, Lin S, Petersen K, Simpson MA, Hoischen A, Gilissen C, Jeffery H, Atton G, Karapouliou C, Brice G, Gordon K, Wiseman JW, Wedin M, Rockson SG, Jeffery S, Mortimer PS, Snyder MP, Berland S, Mansour S, Makinen T and Ostergaard P. EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis. *Journal of Clinical Investigation*. 2016;126:3080-3088.
2. Li D, Wenger TL, Seiler C, March ME, Gutierrez-Uzquiza A, Kao C, Bhoj E, Tian L, Rosenbach M, Liu Y, Robinson N, Behr M, Chiavacci R, Hou C, Wang T, Bakay M, Pellegrino da Silva R, Perkins JA, Sleiman P, Levine MA, Hicks PJ, Itkin M, Dori Y and Hakonarson H. Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. *Hum Mol Genet*. 2018;27:3233-3245.
3. Vivanti A, Ozanne A, Grondin C, Saliou G, Quevarec L, Maurey H, Aubourg P, Benachi A, Gut M, Gut I, Martinovic J, Senat MV, Tawk M and Melki J. Loss of function mutations in EPHB4 are responsible for vein of Galen aneurysmal malformation. *Brain*. 2018;141:979-988.
4. Duran D, Zeng X, Jin SC, Choi J, Nelson-Williams C, Yatsula B, Gaillard J, Furey CG, Lu Q, Timberlake AT, Dong W, Sorscher MA, Loring E, Klein J, Allocco A, Hunt A, Conine S, Karimy JK, Youngblood MW, Zhang J, DiLuna ML, Matouk CC, Mane S, Tikhonova IR, Castaldi C, Lopez-Giraldez F, Knight J, Haider S, Soban M, Alper SL, Komiyama M, Ducruet AF, Zabramski JM, Dardik A, Walcott BP, Stapleton CJ, Aagaard-Kienitz B, Rodesch G, Jackson E, Smith ER, Orbach DB, Berenstein A, Bilguvar K, Vikkula M, Gunel M, Lifton RP and Kahle KT. Mutations in Chromatin Modifier and Ephrin Signaling Genes in Vein of Galen Malformation. *Neuron*. 2019;101:429-443.e4.
5. Amyere M, Revencu N, Helaers R, Pairet E, Baselga E, Cordisco M, Chung W, Dubois J, Lacour JP, Martorell L, Mazereeuw-Hautier J, Pyeritz RE, Amor DJ, Bisdorff A, Blei F, Bombei H, Domp Martin A, Brooks D, Dupont J, Gonzalez-Ensenat MA, Frieden I, Gerard M, Kvarnung M, Hanson-Kahn AK, Hudgins L, Laute-Labreze C, McCuaig C, Metry D, Parent P, Paul C, Petit F, Phan A, Quere I, Salhi A, Turner A, Vabres P, Vicente A, Wargon O, Watanabe S, Weibel L, Wilson A, Willing M, Mulliken JB, Boon LM and Vikkula M. Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Dereglating RAS-MAPK Signaling. *Circulation*. 2017;136:1037-1048.
6. Yu J, Streicher JL, Medne L, Krantz ID and Yan AC. EPHB4 Mutation Implicated in Capillary Malformation-Arteriovenous Malformation Syndrome: A Case Report. *Pediatr Dermatol*. 2017;34:e227-e230.
7. Fotiou E, Martin-Almedina S, Simpson MA, Lin S, Gordon K, Brice G, Atton G, Jeffery I, Rees DC, Mignot C, Vogt J, Homfray T, Snyder MP, Rockson SG, Jeffery S, Mortimer PS, Mansour S and Ostergaard P. Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. *Nature Communications*. 2015;6:8085.
8. Lukacs V, Mathur J, Mao R, Bayrak-Toydemir P, Procter M, Cahalan SM, Kim HJ, Bandell M, Longo N, Day RW, Stevenson DA, Patapoutian A and Krock BL. Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia. *Nat Commun*. 2015;6:8329.
9. Albuissou J, Murthy SE, Bandell M, Coste B, Louis-dit-Picard H, Mathur J, Feneant-Thibault M, Tertian G, de Jaureguiberry J-P, Syfuss P-Y, Cahalan S, Garcon L, Toutain F, Rohrllich PS, Delaunay J, Picard V, Jeunemaitre X and Patapoutian A. Dehydrated hereditary

stomatocytosis linked to gain-of-function mutations in mechanically activated PIEZO1 ion channels. *Nature Communications*. 2013;4:1884.

10. Martin-Almedina S, Mansour S and Ostergaard P. Human phenotypes caused by PIEZO1 mutations; one gene, two overlapping phenotypes? *J Physiol*. 2018;596:985-992.
11. Bui HM, Enis D, Robciuc MR, Nurmi HJ, Cohen J, Chen M, Yang Y, Dhillon V, Johnson K, Zhang H, Kirkpatrick R, Traxler E, Anisimov A, Alitalo K and Kahn ML. Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. *J Clin Invest*. 2016;126:2167-80.
12. Jha SK, Rauniyar K, Karpanen T, Leppanen VM, Brouillard P, Vikkula M, Alitalo K and Jeltsch M. Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. *Sci Rep*. 2017;7:4916.
13. Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppanen V-M, Holopainen T, Kivela R, Ortega S, Karpanen T and Alitalo K. CCBE1 Enhances Lymphangiogenesis via A Disintegrin and Metalloprotease With Thrombospondin Motifs-3-Mediated Vascular Endothelial Growth Factor-C Activation. *Circulation*. 2014;129:1962-1971.
14. Brouillard P, Dupont L, Helaers R, Coulie R, Tiller GE, Peeden J, Colige A and Vikkula M. Loss of ADAMTS3 activity causes Hennekam lymphangiectasia-lymphedema syndrome 3. *Hum Mol Genet*. 2017;26:4095-4104.
15. Alders M, Al-Gazali L, Cordeiro I, Dallapiccola B, Garavelli L, Tuysuz B, Salehi F, Haagmans MA, Mook OR, Majoie CB, Mannens MM and Hennekam RC. Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome. *Human Genetics*. 2014;133:1161-1167.
16. Cappello S, Gray MJ, Badouel C, Lange S, Einsiedler M, Srour M, Chitayat D, Hamdan FF, Jenkins ZA, Morgan T, Preitner N, Uster T, Thomas J, Shannon P, Morrison V, Di Donato N, Van Maldergem L, Neuhann T, Newbury-Ecob R, Swinkels M, Terhal P, Wilson LC, Zwijnenburg PJ, Sutherland-Smith AJ, Black MA, Markie D, Michaud JL, Simpson MA, Mansour S, McNeill H, Gotz M and Robertson SP. Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development. *Nat Genet*. 2013;45:1300-8.
17. van Maldergem L, Wetzburger C, Verloes A, Fourneau C and Gillerot Y. Mental retardation with blepharo-naso-facial abnormalities and hand malformations: a new syndrome? *Clin Genet*. 1992;41:22-4.
18. Ivanovski I, Akbaroghli S, Pollazzon M, Gelmini C, Caraffi SG, Mansouri M, Chavoshzadeh Z, Rosato S, Polizzi V, Gargano G, Alders M, Garavelli L and Hennekam RC. Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes. *Am J Med Genet A*. 2018;176:1166-1174.
19. Mansour S, Swinkels M, Terhal PA, Wilson LC, Rich P, Van Maldergem L, Zwijnenburg PJ, Hall CM, Robertson SP and Newbury-Ecob R. Van Maldergem syndrome: further characterisation and evidence for neuronal migration abnormalities and autosomal recessive inheritance. *Eur J Hum Genet*. 2012;20:1024-31.
20. Boone PM, Paterson S, Mohajeri K, Zhu W, Genetti CA, Tai DJC, Nori N, Agrawal PB, Bacino CA, Bi W, Talkowski ME, Hogan BM and Rodan LH. Biallelic mutation of FBXL7 suggests a novel form of Hennekam syndrome. *Am J Med Genet A*. 2020;182:189-194.
21. Erickson RP, Lai LW, Mustacich DJ, Bernas MJ, Kuo PH and Witte MH. Sex-limited penetrance of lymphedema to females with CELSR1 haploinsufficiency: A second family. *Clin Genet*. 2019;96:478-482.

22. Gonzalez-Garay ML, Aldrich MB, Rasmussen JC, Guilliod R, Lapinski PE, King PD and Sevcik-Muraca EM. A novel mutation in CELSR1 is associated with hereditary lymphedema *Vasc Cell*; 2016;8:1.
23. Maltese PE, Michelini S, Ricci M, Maitz S, Fiorentino A, Serrani R, Lazzerotti A, Bruson A, Paolacci S, Benedetti S and Bertelli M. Increasing evidence of hereditary lymphedema caused by CELSR1 loss-of-function variants. *Am J Med Genet A*. 2019;179:1718-1724.
24. Tatin F, Taddei A, Weston A, Fuchs E, Devenport D, Tissir F and Makinen T. Planar cell polarity protein Celsr1 regulates endothelial adherens junctions and directed cell rearrangements during valve morphogenesis. *Dev Cell*. 2013;26:31-44.
25. Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W and Biesecker LG. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. *Am J Med Genet A*. 2015;167A:287-95.
26. Lindhurst MJ, Parker VER, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotzios C, Dixon AK, Helliwell T, O'Rahilly S, Savage DB, Wakelam MJO, Barroso I, Biesecker LG and Semple RK. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. *Nature Genetics*. 2012;44:928-933.
27. Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV, Rialon KL, Guevara CJ, Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, MacLellan RA, Mulliken JB, Rahbar R, Spencer SA, Trenor CC, 3rd, Upton J, Zurakowski D, Perkins JA, Kirsh A, Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA and Murillo R. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. *J Pediatr*. 2015;166:1048-54.e1-5.
28. Kurek K, Luks V, Ayturk U, Alomari A, Fishman S, Spencer S, Mulliken J, Bowen M, Yamamoto G, Kozakewich H and Warman M. Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome *Am J Hum Genet*; 2012(90): 1108-15.
29. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, Tosi LL, Huson SM, Whitehouse RW, Jakkula E, Grant I, Balasubramanian M, Chandler KE, Fraser JL, Gucev Z, Crow YJ, Brennan LM, Clark R, Sellars EA, Pena LD, Krishnamurty V, Shuen A, Braverman N, Cunningham ML, Sutton VR, Tasic V, Graham JM, Jr., Geer J, Jr., Henderson A, Semple RK and Biesecker LG. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. *Am J Med Genet A*. 2014;164a:1713-33.
30. Al-Olabi L, Polubothu S, Dowsett K, Andrews KA, Stadnik P, Joseph AP, Knox R, Pittman A, Clark G, Baird W, Bulstrode N, Glover M, Gordon K, Hargrave D, Huson SM, Jacques TS, James G, Kondolf H, Kangesu L, Keppler-Noreuil KM, Khan A, Lindhurst MJ, Lipson M, Mansour S, O'Hara J, Mahon C, Mosica A, Moss C, Murthy A, Ong J, Parker VE, Riviere JB, Sapp JC, Sebire NJ, Shah R, Sivakumar B, Thomas A, Virasami A, Waelchli R, Zeng Z, Biesecker LG, Barnacle A, Topf M, Semple RK, Patton EE and Kinsler VA. Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. *J Clin Invest*. 2018;128:1496-1508.
31. Keppler-Noreuil KM, Parker VE, Darling TN and Martinez-Agosto JA. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. *Am J Med Genet C Semin Med Genet*. 2016;172:402-421.
32. Parker VE, Knox RG, Zhang Q, Wakelam MJ and Semple RK. Phosphoinositide 3-kinase-related overgrowth: cellular phenotype and future therapeutic options. *Lancet*. 2015;385 Suppl 1:S77.

33. Vahidnezhad H, Youssefian L and Uitto J. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). *Exp Dermatol.* 2016;25:17-9.
34. Chen CC, Er TK, Liu YY, Hwang JK, Barrio MJ, Rodrigo M, Garcia-Toro E and Herreros-Villanueva M. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. *PLoS One.* 2013;8:e55793.
35. Joyce S, Gordon K, Brice G, Ostergaard P, Nagaraja R, Short J, Moore S, Mortimer P and Mansour S. The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome. *European Journal of Human Genetics.* 2016;24:690-696.
36. Chavhan GB, Amaral JG, Temple M and Itkin M. MR Lymphangiography in Children: Technique and Potential Applications. *Radiographics.* 2017;37:1775-1790.
37. Biko DM, Reisen B, Otero HJ, Ravishankar C, Victoria T, Glatz AC, Rome JJ and Dori Y. Imaging of central lymphatic abnormalities in Noonan syndrome. *Pediatr Radiol.* 2019;49:586-592.
38. Rossi M, Buonomo PS, Battafarano G, Conforti A, Mariani E, Algeri M, Pelle S, D'Agostini M, Macchiaiolo M, De Vito R, Gonfiantini MV, Jenkner A, Rana I, Bartuli A and Del Fattore A. Dissecting the mechanisms of bone loss in Gorham-Stout disease. *Bone.* 2020;130:115068.
39. Ricci KW, Hammill AM, Mobberley-Schuman P, Nelson SC, Blatt J, Bender JLG, McCuaig CC, Synakiewicz A, Frieden IJ and Adams DM. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. *Pediatr Blood Cancer.* 2019;66:e27614.